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INTRODUCTION 
 
 “The world is facing a global pandemic of chronic kidney 
disease. As the morbidity and mortality from infectious diseases 
decline, life expectancy increases and chronic degenerative diseases 
have become more prevalent. CKD is unique amongst the chronic 
non-infectious illnesses…..”.1  
 It has been estimated from population survey data that atleast 
6% of the adult population in the United States has CKD at stages 1 
and 2. An unknown subset of this group will progress to more 
advanced stages of CKD. An additional 4.5% of the U.S. 
population is estimated to have stages 3 and 4 CKD. The most 
frequent cause of CKD is diabetic Nephropathy, most often 
secondary to Type 2 DM.2  
India being the diabetic capital of the world, diabetic 
Nephropathy is the commonest cause of CKD. There are about 7.85 
million CKD patients in India.3  
Patients with End Stage Renal Disease display a variety of 
endocrine disturbances. However the evidence of endocrine 
dysfunction commonly consists only of laboratory abnormalities, 
many of which are not associated with apparent clinical signs and 
symptoms of the disease.4 Among which Thyroid function has been 
extensively evaluated in patients with CRF. 
CRF is a widely recognised cause of nonthyroidal illness 
causing thyroid dysfunction, ie, alteration in thyroid hormones in 
the absence of underlying intrinsic thyroid disorder.5,19  
Chronic renal failure affects thyroid function in multiple 
ways, including low circulating thyroid hormone concentration, 
altered peripheral hormone metabolism, disturbed binding to carrier 
proteins, possible reduction in tissue thyroid content and increased 
iodine stores in thyroid glands. 
 TT3, TT4, FT3 are decreased more commonly in patients with 
CRF. But FT4, TSH levels are normal in these patients and indicate 
euthyroid status. We speculate that the low thyroid state in uremia 
serves to defend against protein wasting and misguided attempts to 
replete thyroid hormone stores may worsen protein malnutrition.6  
Some studies showed an increased incidence of subclinical 
hypothyroidism in CKD patients and higher prevalence of 
hypothyroidism in patients with terminal renal failure.7  
It has been estimated that primary hypothyroidism may occur 
in upto 9.5% of ESRD patients when compared to  0.6 to 1.1% of 
general population.7 
When hypothyroidism becomes more severe it can cause 
reduced cardiac function and lead to progressively worsening 
kidney function. Thus the prevalence of subclinical hypothyroidism 
in patients with CKD might be a risk factor for both cardiovascular 
disease and progressive kidney disease.8 
This study is designed to determine the prevalence of thyroid 
dysfunction in CRF patients in order to intervene at an early stage 
depending upon the hormone abnormalities and reduce both the 
cardiovascular risk and progressive worsening of kidney function.  
REVIEW OF LITERATURE 
 
DEFINITIONS: 
1.  CKD :    
Chronic kidney disease encompasses a spectrum of different 
pathophysiological processes associated with abnormal kidney 
function and a progressive decline in GFR. 
 CKD is classified into five stages according to the 
guidelines given by National Kidney Foundation (NKF) / (Kidney 
Dialysis outcome Quality Initiative (KDOQI)).2 
2.   CRF: 
 Chronic Renal Failure applies to the process of 
continuing significant irreversible reduction in nephron number 
and typically corresponds to CKD stages 3 to 5. 2  
3. ESRD:    
End Stage Renal Disease represents stage 5 CKD where the  
accumulation of toxins, fluids and electrolytes results in uremic 
syndrome.2                           
 
 
STAGES OF CRF 
 
Stage Description GFR ml/mt per 
1.73 m2
1. Kidney damage with normal or increased 
GFR 
≥ 90 
2. Kidney damage with mildly decreased GFR 60 - 89 
3. Moderately decreased GFR 30 – 59 
4. Severely decreased GFR 15 – 29 
5. Kidney failure < 15 or dialysis 
 Recommended Equations for estimation of GFR using 
serum creatinine (Pcr), Age, Sex, Race and Body weight. 
1. Cockcroft – Gault  Equation: 
Estimated creatinine clearance (ml/mt) 
 
     (140-Age)  X   body weight  in k.g. 
   =                  
                72   X  Pcr (mg/dl)  
                           (multiply by 0.85 for women) 
 
2. MDRD Formula : (Modification of Diet in Renal Disease 
study) 
Estimated GFR (ml/mt per 1.73 m2) 
=  1.86 x  (Pcr)– 1.154  x (Age) -0.203 
          Multiply by 0.742 for women  
        Multiply by 1.21 for African Americans. 
AETIOLOGY OF CRF1: 
1. Diabetes Mellitus  
2. Hypertension 
3. Chronic glomerulonephritis  
4. Chronic pyelonephritis 
5. Hereditary and cystic diseases of Kidney  
6. Obstructive uropathy and others. 
PREVALENCE OF VARIOUS TYPES OF CKD IN INDIA9
S.No. Aetiology Indian Population 
1. Diabetes Mellitus  27.4% 
2. Hypertension  15.5% 
3. Glomerulonephritis  19.3% 
4. Interstitial Nephritis 8.6% 
5. Cystic/ Hereditary diseases 3.9% 
6. Miscellaneous 12.1% 
7. Unknown 13.2% 
 Total 100% 
 
Source:  
Data from the All India CKD registry of the Indian Society of 
Nephrology. 
Clinical Abnormalities in Uremia2
 
Fluid and electrolyte 
disturbances 
Volume expansion  
Hyponatremia  
Hyperkalemia  
Hyperphosphatemia  
Endocrine-metabolic 
disturbances 
Secondary 
hyperparathyroidism  
Adynamic bone  
Vitamin D–deficient 
osteomalacia  
Carbohydrate resistance  
Hyperuricemia  
Hypertriglyceridemia  
Increased Lp(a) level  
Decreased high-density 
lipoprotein level  
Protein-energy 
malnutrition  
Impaired growth and 
development  
Infertility and sexual 
dysfunction  
Amenorrhea  
Neuromuscular 
disturbances 
Fatigue  
Sleep disorders  
Headache  
Impaired mentation  
Lethargy  
Asterixis  
Muscular irritability 
Peripheral neuropathy  
Restless legs syndrome  
Myoclonus  
Seizures  
Coma  
Muscle cramps   
Myopathy  
Cardiovascular and 
pulmonary disturbances 
Arterial hypertension  
Congestive heart failure or 
pulmonary edema  
Pericarditis  
Hypertrophic or dilated 
cardiomyopathy  
Uremic lung  
Accelerated atherosclerosis  
Dermatologic disturbances 
Pallor  
Hyperpigmentation  
Pruritus  
Ecchymoses  
Nephrogenic fibrosing 
dermopathy  
Uremic frost  
Gastrointestinal disturbances 
Anorexia  
Nausea and vomiting  
Gastroenteritis  
Peptic ulcer  
Gastrointestinal bleeding  
Idiopathic ascites  
Peritonitis  
Hematologic and immunologic 
disturbances 
Anemia  
Lymphocytopenia  
Bleeding diathesis  
Increased susceptibility to 
infection  
Leukopenia  
Thrombocytopenia  
 
Thyroid hormone secretion, transport and action: 
 Thyroid gland secretes predominantly thyroxine (T4) and only 
a small amount of Triiodothyronine(T3). Production of T3 and T4 in 
the thyroid is stimulated by Thyroid stimulating hormone (TSH), 
released from the anterior pituitary in response to stimulation by 
thyrotropin releasing hormone (TRH), released by hypothalamus. In 
turn TSH and TRH secretions are inhibited by T4, forming a 
negative feedback loop that keeps free T4 level within a narrow 
range. 
 Thyroid hormones exist in circulation in both free and bound 
forms. About 80% of thyroid hormone is bound to thyroxine binding 
globulin (TBG). TBG has high affinity for thyroid hormones 
(T4>T3). Albumin has relatively low affinity for thyroid hormones 
and it binds upto 10% of T4 and 30% T3. Transthyretin carries about 
10% of T4 and little T3. When the effects of various binding 
proteins are combined, approximately 99.98% of T4 and 99.7% of 
T3 are protein bound. But only the unbound form is biologically 
active and exerts its metabolic actions after binding to nuclear 
thyroid hormone receptors which have 15 fold higher affinity for T3 
than T4. So in metabolically active tissues,  T4 is converted into T3 
by deiodinase enzymes.40
HYPOTHYROIDISM 
DEFINITIONS10: 
1. HYPOTHYROIDISM: 
Syndrome caused by thyroid hormone deficiency. 
      Primary Hypothyroidism – Primary defect in the thyroid                       
gland to synthesise and secrete thyroid hormones. 
    Secondary Hypothyroidism – Due to TSH deficiency  
   secondary to disorders of pituitary and  hypothalamus. 
1. Subclinical Hypothyroidism28: 
Increased TSH usually <20 mU/L but normal free T4. 
Only minor symptoms are present. 
2. Clinical / Overt Hypothyroidism:  
      Increased TSH usually >20 mU/L and decreaed free T4. 
      Prominent signs and symptoms of hypothyroidism are present.  
SIGNS AND SYMPTOMS OF HYPOTHYROIDISM 10,28:  
1. Lethargy and tiredness 
2. dry skin 
3. cold intolerance  
4. Hair loss 
5. Poor concentration and memory  
6. constipation  
7. Hoarseness of voice 
8. Weight gain with poor appetite  
9. Menorrhagia and loss of libido 
10. Impaired hearing 
11. Myxedema (puffiness of face, hands and feet) 
12. Bradycardia  
13. Delayed relaxation of tendon reflexes (Pseudo myotonic 
reflex) 
Laboratory Evaluation of Hypothyroidism 40
A normal TSH level excludes primary (but not secondary) 
hypothyroidism. If the TSH is elevated, an unbound T4 level is 
needed to confirm the presence of clinical hypothyroidism, but T4 
is inferior to TSH when used as a screening test, as it will not detect 
subclinical hypothyroidism. Circulating unbound T3 levels are 
normal in about 25% of patients, reflecting adaptive deiodinase 
responses to hypothyroidism. T3 measurements are therefore not 
indicated. 
Once clinical or subclinical hypothyroidism is confirmed, the 
etiology is usually easily established by demonstrating the presence 
of TPO antibodies, which are present in >90% of patients with 
autoimmune hypothyroidism. TBII can be found in 10–20% of 
patients, but these determinations are not needed routinely. If there 
is any doubt about the cause of a goiter associated with 
hypothyroidism, FNA biopsy can be used to confirm the presence 
of autoimmune thyroiditis. Other abnormal laboratory findings in 
hypothyroidism may include increased creatine phosphokinase, 
elevated cholesterol and triglycerides, and anemia (usually 
normocytic or macrocytic). Except when accompanied by iron 
deficiency, the anemia and other abnormalities gradually resolve 
with thyroxine replacement 
Hypothyroidism: Treatment  40
Clinical Hypothyroidism 
If there is no residual thyroid function, the daily replacement 
dose of levothyroxine is usually 1.6 mcg/kg body weight (typically 
100–150 mcg).  
Adult patients under 60 without evidence of heart disease 
may be started on 50–100 mcg levothyroxine (T4) daily. The dose 
is adjusted on the basis of TSH levels, with the goal of treatment 
being a normal TSH, ideally in the lower half of the reference 
range. TSH responses are gradual and should be measured about 2 
months after instituting treatment or after any subsequent change in 
levothyroxine dosage. The clinical effects of levothyroxine 
replacement are often slow to appear. Patients may not experience 
full relief from symptoms until 3–6 months after normal TSH 
levels are restored. Adjustment of levothyroxine dosage is made in 
12.5- or 25-mcg increments if the TSH is high; decrements of the 
same magnitude should be made if the TSH is suppressed. Patients 
with a suppressed TSH of any cause, including T4 over treatment, 
have an increased risk of atrial fibrillation and reduced bone 
density. 
 There is no place for liothyronine alone as long-term 
replacement, because the short half-life necessitates three or four 
daily doses and is associated with fluctuating T3 levels. 
Once full replacement is achieved and TSH levels are stable, 
follow-up measurement of TSH is recommended at annual intervals 
and may be extended to every 2–3 years if a normal TSH is 
maintained over several years. It is important to ensure ongoing 
adherence, however, as patients do not feel any symptomatic 
difference after missing a few doses of levothyroxine, and this 
sometimes leads to self-discontinuation. 
In patients of normal body weight who are taking 200 mcg of 
levothyroxine per day, an elevated TSH level is often a sign of poor 
adherence to treatment. T4 has a long half-life (7 days), patients 
who miss doses can be advised to take two or three doses of the 
skipped tablets at once. Other causes of increased levothyroxine 
requirements must be excluded, particularly malabsorption (e.g., 
celiac disease, small-bowel surgery), estrogen therapy, and drugs 
that interfere with T4 absorption or clearance such as 
cholestyramine, ferrous sulfate, calcium supplements, lovastatin, 
aluminum hydroxide, rifampicin, amiodarone, carbamazepine, and 
phenytoin. 
Subclinical Hypothyroidism 
By definition, subclinical hypothyroidism refers to 
biochemical evidence of thyroid hormone deficiency in patients 
who have few or no apparent clinical features of hypothyroidism. 
There are no universally accepted recommendations for the 
management of subclinical hypothyroidism, but the most recently 
published guidelines do not recommend treatment when TSH levels 
are below 10 mU/L. It is important to confirm that any elevation of 
TSH is sustained over a 3-month period before treatment is given. 
As long as excessive treatment is avoided, there is no risk in 
correcting a slightly increased TSH. Moreover, there is a risk that 
patients will progress to overt hypothyroidism, particularly when 
the TSH level is elevated and TPO antibodies are present. 
Treatment is administered by starting with a low dose of 
levothyroxine (25–50 mcg/d) with the goal of normalizing TSH. If 
thyroxine is not given, thyroid function should be evaluated 
annually. 
Special Treatment Considerations 
  Elderly patients may require up to 20% less thyroxine than 
younger patients. In the elderly, especially patients with known 
coronary artery disease, the starting dose of levothyroxine is 12.5–
25 mcg/d with similar increments every 2–3 months until TSH is 
normalized. In some patients it may be impossible to achieve full 
replacement, despite optimal antianginal treatment. Emergency 
surgery is generally safe in patients with untreated hypothyroidism, 
although routine surgery in a hypothyroid patient should be 
deferred until euthyroidism is achieved. 
Thyroid function should be evaluated immediately after 
pregnancy is confirmed and at the beginning of the 2nd and 3rd 
trimesters.The dose of levothyroxine may need to be increased by 
≥50% during pregnancy and return to previous levels after delivery.  
Myxedema coma still has a high mortality rate, despite intensive 
treatment. Clinical manifestations include reduced level of 
consciousness, sometimes associated with seizures, as well as the 
other features of hypothyroidism. Hypothermia can reach 23°C 
(74°F). There may be a history of treated hypothyroidism with poor 
compliance, or the patient may be previously undiagnosed. 
Myxedema coma almost always occurs in the elderly and is usually 
precipitated by factors that impair respiration, such as drugs 
(especially sedatives, anesthetics, antidepressants), pneumonia, 
congestive heart failure, myocardial infarction, gastrointestinal 
bleeding, or cerebrovascular accidents. Sepsis should also be 
suspected. Exposure to cold may also be a risk factor. 
Hypoventilation, leading to hypoxia and hypercapnia, plays a major 
role in pathogenesis; hypoglycemia and dilutional hyponatremia 
also contribute to the development of myxedema coma. 
Levothyroxine can initially be administered as a single 
intravenous bolus of 500 mcg, which serves as a loading dose. 
Although further levothyroxine is not strictly necessary for several 
days, it is usually continued at a dose of 50–100 mcg/d. If suitable 
intravenous preparation is not available, the same initial dose of 
levothyroxine can be given by nasogastric tube (though absorption 
may be impaired in myxedema). An alternative is to give 
liothyronine (T3) intravenously or via nasogastric tube, in doses 
ranging from 10 to 25 mcg every 8–12 h. This treatment has been 
advocated because T4 to T3 conversion is impaired in myxedema 
coma. However, excess liothyronine has the potential to provoke 
arrhythmias. Another option is to combine levothyroxine (200 mcg) 
and liothyronine (25 mcg) as a single, initial intravenous bolus 
followed by daily treatment with levothyroxine (50–100 mcg/d) 
and liothyronine (10 mcg every 8 h). 
Supportive therapy should be provided to correct any 
associated metabolic disturbances. External warming is indicated 
only if the temperature is <30°C, as it can result in cardiovascular 
collapse . Space blankets should be used to prevent further heat 
loss. Parenteral hydrocortisone (50 mg every 6 h) should be 
administered, as there is impaired adrenal reserve in profound 
hypothyroidism. Any precipitating factors should be treated, 
including the early use of broad-spectrum antibiotics, pending the 
exclusion of infection. Ventilatory support with regular blood gas 
analysis is usually needed during the first 48 h. Hypertonic saline or 
intravenous glucose may be needed if there is severe hyponatremia 
or hypoglycemia; hypotonic intravenous fluids should be avoided 
because they may exacerbate water retention secondary to reduced 
renal perfusion and inappropriate vasopressin secretion. The 
metabolism of most medications is impaired, and sedatives should 
be avoided if possible or used in reduced doses. Medication blood 
levels should be monitored, when available, to guide dosage 
THYROID DYSFUNCTION IN CRF: 
 Chronic Renal Failure can cause various endocrine 
abnormalities, among which thyroid dysfunction is most important 
one and extensively evaluated by various research workers.  
 Chronic renal failure affects thyroid function in multiple 
ways6.  
1. Low circulating thyroid hormone concentration – 
  TT3,TT4,FT3 are reduced29. 
2. Altered peripheral hormone metabolism. 
3. disturbed binding to carrier proteins  
4. possible reduction in tissue thyroid hormone content. 
5. Increased Iodine stores in thyroid glands 35,37. 
 
Low serum T3 is not due to increased T3 degradation or to 
decreased T3 secretion from thyroid but is a result of impaired 
extra thyroidal peripheral conversion of T4 to T3.33 
The reduction in T4 is attributed to the presence of 
circulating inhibitors (uremic toxins) which impair binding of T4 
to Thyroxine binding globulin (TBG)12,30. 
Despite decreased circulating T4 and T3, thyroid stimulating 
hormone (TSH) level in serum is not elevated. This absence of 
TSH elevation is not due to dysfunction of hypothalamo-pituitary 
axis, because truly hypothyroid renal failure patients can mount a 
high TSH response.34
 Thyroid hormone losses during Hemodialysis and peritoneal 
dialysis are trivial and do not require replacement. Serum 
inorganic iodide and thyroidal iodide content are increased in CRF 
patients and thyroid gland enlargement (goitre) is also frequently 
encountered 6,35,37. 
 In addition to reduction in TT3, TT4, FT3 levels in serum, 
some other abnormalities in thyroid hormone metabolism are also 
reported. These may include elevated bastal TSH values, which 
may transiently increased to greater than 10mU/L, blunted TSH 
response to  TRH, decreased or absent TSH diurnal rhythm, 
altered TSH glycosylation and impaired TSH & TRH clearance 
rates.11,31,36 
 Thus multitude of defects at all levels of hypothalamo-
pituitary – thyroido peripheral axis does seem to exist in uremia.13 
 Dialysis therapy minimally affects thyroid hormone 
metabolism while Zinc, Erythropoietin administration may 
partially reverse these abnormalities. Thyroid hormone 
metabolism normalises with renal transplantation.32
There have been speculations on the nature of the 
presumptive inhibitors in uremia patients and drugs have been 
accounted for low T3 and T4 levels14. 
Frusemide and heparin may influence the thyroid hormone 
levels. Frusemide inhibits T3,T4 binding to serum proteins at high 
levels16. Heparin acutely raises both TT4 & FT4 levels in blood.15  
Other drugs known to suppress the thyroid hormone level 
are glucocorticoids, propranolol, sulphonylurea, phenytoin and 
phenobarbitone. 
Goitre and hypothyroidism may be induced by iodide excess 
due to reduced renal iodide excretion. 35,37 
CARDIOVASCULAR EFFECTS OF MILD 
HYPOTHYROIDISM 20,39 
 Many patients with CKD have mild reduction in Thyroid 
function or subclinical hypothyroidism – a condition that becomes 
more common as kidney function declines, according to a study in 
the September 2008 issue of clinical journal of the American 
Society of Nephrology (CJASN).8 
 Patients with CKD are greatly increased risk of 
cardiovascular disease. Cardiovascular disease remains the most 
common cause of death in patients with ESRD, and CKD patients 
are more likely to die from cardiovascular disease than are 
expected to progress to ESRD.  The CKD population has a higher 
incidence of traditional cardiovascular risk factors, including 
diabetes, hypertension and dyslipidemias. In addition 
overwhelming scientific evidence has shown that decreased GFR 
and proteinuria are independent risk factors for cardiovascular 
disease. When sub clinical hypothyroidism coexists, they suffer 
more decline in cardiac function and progressive kidney disease.  
 
Complications of CKD worsened by coexisting 
hypothyroidism are, 
I. Cardiovascular Complications 
• Secondary hypertension 
• LV failure and pulmonary edema 
• Accelerated atherosclerosis 
• Myocardial infarction 
• Pericarditis  
• Uremic cardiomyopathy 
Hypothyroidism is often associated with elevated LDL-c 
levels due to a reduction in hepatic LDL receptor formation and 
delayed clearance of LDL.41  
 
II. CNS and neuromuscular complications 
• Dementia 
• Uremic encephalopathy 
• Peripheral neuropathy  
• Proximal muscle weakness 
III. Hematological complications like anemia  
Hypothyroidism can cause normocytic normochromic, 
macrocytic anemia or iron deficiency anemia due to menorrhagia. 
IV. Electrolyte imbalance like hyponatremia  
Hypothyroidism can cause euvolumic hypoosmolar 
hyponatremia. The occurrence of hyponatremia with 
hypothyroidism generally suggests severe disease, including 
myxedema coma.42
V. Fluid overload – edema. 
Myxedema may worsen the volume overload state of CRF.  
 
 
 
 
 
TECHNIQUES USED TO ASSESS THE CARDIOVASCULAR 
DYSFUNCTION 
1. Pulsed tissue Doppler echo  
2. Radionuclide Ventriculography 
3. Ultrasonic myocardial textural analysis  
4. Cardiac MRI 
LV DIASTOLIC DYSFUNCTION: 
Characterised by  
1. Prolonged isovolumetric relaxation time and impaired LV 
filling. - Due to decreased expression of sarcoplasmic reticulum 
ATPase or increased expression of phospholamban. 
2.   Decreased E/A ratio :- 
           Early diastolic mitral flow velocity  
   =           
    Late diastolic mitral flow velocity 
LV Systolic dysfunction: 
1. Increased PEP/ET 
PEP – Preejection period 
ET-  Ejection time 
2. Precontraction Time and myocardial relaxation time both are 
prolonged. 
3. Changes in the myocardial time intervals in several LV 
segments are noted.  
4. Posterior septum & mitral leaflet annulus are the most 
affected regions. 
5. Preload (EDV) is decreased  
6. After load (SVR) is increased 
- Due to loss of vasodilatory effects of thyroid hormones.  
All these factors cause reduction in cardiac performance.  
Abnormal diastolic function may impair coronary flow reserve. 
 
EFFECTS ON VASCULAR SYSTEM: 
1. Increased Systemic Vascular Resistance (SVR) 
2. Increased arterial stiffness indicated by increased brachial 
 ankle pulse wave velocity  
3. Endothelial dysfunction due to impaired Nitric Oxide (NO)  
 availability. 
4. All these factors predispose to  diastolic HT. 
 
 
 
PREVALENCE OF THYROID DYSFUNCTION: 
A Major contribution in this field is by Ramirez and 
associates, who reported upto 58% prevalence of goiter in CRF 
patients.16 
Recently, Quoin-verde et al have also reported a higher 
prevalence of upto 5% of hypothyroidism in patients with terminal 
renal failure in comparison with that in hospitalised patients with 
normal renal function(0.6%). 17
In one study, overall 9.5% of patients with CKD had 
subclinical hypothyrodism with no abnormal symptoms or signs.  
7% of mild CKD patients had low thyroid function when 
compared to 18% of those with moderate CKD. After adjustment 
of other factors patients with moderate CKD were 73% more 
likely to have some thyroid hormone abnormalities38 in the form 
of reduction in TT3, TT4 or FT3
Treatment of thyroid dysfunction in CRF:- 
 Experiments performed to correct the low serum T3 level by 
administration of small doses of LT3 resulted in lesser nitrogen 
balance and protein degradation. So we speculate that low thyroid 
state in uremia serves to defend against protein wasting and that 
misguided attempts to replete thyroid hormone stores may worsen 
protein malnutrition.6 
 CKD at all stages constitute a major risk factor for ischemic 
cardiovascular disease including coronary heart disease because  
CKD is a state  of accelerated atherosclerosis.  
Coexisting subclinical/overt hypothyroidism should be treated 
to reduce the cardiovascular risk and retard the progression of 
kidney disease.  
CKD related risk factors22 for cardiovascular disease other 
than secondary HT are  
1. Anemia 
2. Hyperphosphatemia 
3. Hyperparathyroidism. 
4. Generalised inflammation (evidenced by increased CRP). 
5. Sleep apnea  
“Although no recommendations are available regarding the 
treatment of mild abnormalities of thyroid hormone levels in patients 
with CKD, these abnormalities could represent a risk factor for 
cardiovascular  disease and might also be implicated  in kidney 
disease progression” comments given by authors Dr.Michel 
Chonchol of University of Colorado health sciences centre and 
Dr.Giovanni Targher of University of Verona, Italy.21 
  
 
 
AIM OF THE STUDY 
 
1. To determine the prevalence of thyroid dysfunction in  
   chronic renal failure patients in stages 3,4 and 5. 
2. To correlate the prevalence of thyroid hormone  
   abnormalities with increasing degrees of renal  
  insufficiency. 
MATERIALS AND METHODS 
Subjects:  
Patients admitted in the department of medicine and 
nephrology who fulfilled the inclusion and exclusion criteria. 
Study design:  
Cross sectional study. 
Ethical committee approval:  
Approval was obtained to carry out the study in Govt.Rajaji 
Hospital, Madurai. 
Study setting:   
Govt. Rajaji Hospital, Madurai  
Study Duration:  
August  2008 to October 2009 
Study Criteria:  
Inclusion Criteria:  
Newly detected CRF patients with chronic renal insufficiency 
defined as  
1. An estimated creatinine clearance of < 60 ml/mt.(Stages 3,4&5). 
2. USG evidence of chronic renal failure. 
 
Exclusion Criteria: 
1) Previously known hypothyroid patients  
2) Patients on high dose of frusemide therapy  > 100 mg/day. 
3) On heparin therapy  
4) On steroid therapy 
5) On antiepileptics like phenytoin, phenobarbitone 
6) On sulphonylureas. 
7) On propranolol. 
Study Protocol:  
Patients admitted in the department of medicine or 
nephrology in GRH were included in the study according to the 
criteria after getting informed consent. A well designed proforma 
was used to collect the demographic and clinical details of the 
patients. 
Limitations of the study:  
1. Small sample size. (only 40 patients) 
2. Prevalence of hypothyroidism increases as the age advances. 
So we have to consider the influence of age on hypothyroidism. 
3. Geographical variation of goiter and thyroid problems. 
 
Collaborating departments:  
1. Dept. of Medicine  
2. Dept. of Nephrology  
3. Dept. of Endocrinology  
Sample collection: 
A sample of 40 patients was collected defining the stage 3 to 
5 CKD.  
Serum creatinine was measured using the modified kinetic 
jaffe method. 
Kidney function was assessed by estimated creatinine 
clearance which was calculated by using the cockcroft – gault 
formula 
      (140 – Age) X Body Weight in kg 
  =           
    72 X Pcr (mg/dl) 
   multiply by 0.85 for women. 
 
 Thyroid function was assessed by measuring TT3, TT4, FT3, 
FT4 and TSH level in serum.  
Methods: 
1. Blood urea estimation was done by using diacetyl 
monoxime (DAM) method. 
2. Serum creatinine estimation was done by modified kinetic 
jaffe method. 
3. Serum TT3, TT4, FT3 and  FT4  were estimated by 
competitive chemiluminescent immuno assay. 
4. TSH estimation was done by ultra sensitive sandwich 
chemiluminescent immuno assay. 
5. USG abdomen to assess the kidney size and morphology  
Statistical Analysis: 
 The information collected regarding all the selected cases 
were recorded in the master chart. Data analysis was done with the 
help of computer using Epidemiological Information Package -
2002 (EPI Info 2002). 
 Using this software range, frequencies, percentages, means, 
standard deviations, Chi-square and ‘p’ values were calculated. 
Kruskul wallis chi-square test was used to test the significance of 
difference between quantitative variables and Yate’s tests for 
qualitative variables A ‘p’ value less than 0.05 is taken to denote 
significant relationship.  
OBSERVATION AND RESULTS 
 
Table -1 : Age Distribution  
Cases Age Group 
(yrs) Numbers % 
21 – 30 4 10.0 
31 – 40 7 17.5 
41 – 50 10 25.0 
51 – 60 14 35.0 
>60 5 12.5 
Total 40 100 
Range 23 to 75 yrs 
Mean 48.5 yrs 
S.D 12.6 yrs 
 
Most of the patients in the sample were in the age group of 
51-60 years. The range was from 23 to 75 years. 
  
 
 
Table 2: Sex 
 
Cases  
Sex Numbers % 
Male 30 75 
Female 10 25 
Total  40 100 
 
Of the 40 patients in the sample 30 patients were males, and 
10 patients were females. 
 
 
 
 
 
 
  
 
 
Table -3: Diabetes Mellitus 
 
Cases DM 
Numbers % 
Yes 11 27.5 
No 29 72.5 
Total  40 100 
 
Of the 40 patients with CRF, 11 patients (27.5%) were 
diabetic. 
  
 
 
Table -4: Symptoms of Hypothyroidism 
 
Cases  
Symptoms Numbers % 
Yes 8 20 
No 32 80 
Total 40 100 
 
Of the 40 patients with CRF, 8 patients (20%) only were 
symptomatic and majority (80%) were asymptomatic. 
 
 
 
 
 
 
  
 
Table -5: Goitre 
 
Cases  
Goitre 
 
Numbers % 
Yes 7 17.5 
No 33 82.5 
Total 40 100 
 
Of the 40 patients with CRF, 7 patients (17.5%) had goiter. 
  
 
Table -6: CRF Stage 
 
Cases  
CRF STAGE 
 
Numbers % 
3 6 15 
4 11 27.5 
5 23 57.5 
Total 40 100 
 
Of the 40 patients in this sample, 6 patients belonged to stage 
3, 11 patients to stage 4 and 23 patients to stage 5. 
 
 
 
 
 
  
 
Table -7: Relationship between CRF Stage and Symptoms 
of hypothyroidism 
 
Symptoms  
YES NO 
 
CRF STAGE 
(No.of Pts) Number % Number % 
3 (6) - - 6 10.0 
4 (11) 1 9.1 10 90.9 
5 (23) 7 30.4 16 69.6 
 
The Table shows that symptoms of hypothyroidism are 
prominent with advanced stages of renal failure.  
 
 
 
 
 
 Table -8: Thyroid dysfunction 
 
Cases  
Impression Numbers % 
Hypothyroidism 3  7.5 
Sub clinical 
hypothyroidism 
6 15.0 
Some hormone 
abnormalities 
17 42.5 
Normal  14 35.0 
Total 40 100 
 
Of the 40 patients in this sample,  
3 patients (7.5%) had hypothyroidism 
6 patients (15%) had subclinical hypothyroidism 
17 patients (42.5) had some thyroid hormone abnormalities. 
Totally 26 patients (65%) had some thyroid dysfunction. 
  
 
Table -9: Relationship between CRF Stage & Goitre 
 
Goitre 
YES NO 
 
CRF STAGE 
(No.of Pts) Number % Number % 
3(6) - - 6 100 
4(11) 1 9.1 10 90.9 
5(23) 6 26.1 17 73.9 
 
Of the 40 patients in this study group 23 patients had stage 
5CKD. The prevalence of goiter was  0% in stage 3 CKD, 9.1% in 
stage 4 CKD and 26.1% in stage 5 CKD. The higher the stage of 
CKD, the higher was the prevalence of goiter. 
 
 
 
 
Table -10: Relationship between CRF Stage  
& thyroid dysfunction 
 
Of the 40 patients in the study group, 23 patients had stage 5 
CKD. 13% of  stage 5 CKD pts had hypothyroidism when 
compared to stage 3 (0%) and stage 4(0%). 21.7% of  stage 5 CKD 
patients had sub clinical hypothyroidism when compared to stage 
3(0%) and stage 4 (9.1%). Some hormone abnormalities in stages 
3,4 &5 CKD were 16.7%, 54.5% and 43.5% respectively. So 
higher the stage of CKD, higher was the prevalence of thyroid 
dysfunction. This correlation was found to be statistically 
significant. 
CRF  STAGE 
3 4 5 
 
Thyroid  
Dysfunction No % No % No % 
Hypothyroidism - - - - 3 13 
Subclinical  
Hypothyroidism 
- - 1 9.1 5 21.7 
Other hormone 
abnormalities 
1 16.7 6 54.5 10 43.5 
Normal 5 83.3 4 36.4 5 21.7 
Total 6 100 11 100 23 100 
Table -11: Relationship between CRF Stage & hematological 
parameters and their significance. 
 
 
 
CRF STAGE 
3 4 
 
5 
 
Parameter 
Mean SD Mean SD Mean SD 
‘p’ value 
 and its 
significance 
Blood Sugar 87 9.1 109.9 36.3 96.3 20.6 0.3235 not 
significant 
Blood Urea 75.8 15.2 93.6 11.6 137.4 33.4 0.0001 
significant 
Serum 
creatinine 
2.13 0.22 3.39 0.26 7.93 2.33 0.0001 
significant 
TT3 105.2 16.0 99 43.8 74.4 25.0 0.0375  
significant 
TT4 6.19 0.94 5.06 1.1 4.32 1.57 0.0254 
significant 
FT3 2.59 0.29 2.1 0.53 1.74 0.54 0.0043 
significant 
FT4 1.11 0.21 1.04 0.22 0.91 0.18 0.1148 
not significant 
TSH 2.08 0.47 3.51 2.05 5.7 3.27 0.0031  
significant 
Table -12 : Relationship between Thyroid dysfunction and hematological parameters and their significance 
 
 
 
 
 
 
Thyroid dysfunction 
Hypothyroidism Subclinical Thyroidism 
Other 
abnormalities 
 
Normal 
 
 
Parameter 
 
Mean 
 
SD 
 
Mean 
 
SD 
 
Mean 
 
SD 
 
Mean 
 
SD 
 
‘p’ value and 
its 
significance 
Blood Sugar 107        27.7 90.0 13.9 105.1 32.4 92.9 17.9 0.7649  Not Significant 
Blood Urea 136        11.1 125.8 35.0 128.5 43.4 92.6 18 0.0222 Significant 
Serum 
creatinine 9.0        2.55 6.53 2.63 6.64 3.4 3.81 1.61
0.0085 
Significant 
TT3 43.0        5.2 85.7 9.2 75.3 35.3 107.7 23 0.0003 Significant 
TT4 1.89        1.07 5.28 0.27 3.96 0.69 6.25 0.86 0.0001 Significant 
FT3 1.23        0.26 2.17 0.49 1.69 0.49 2.37 0.47 0.0001 Significant 
FT4 0.55        0.11 0.9 0.06 0.95 0.15 1.14 0.16 0.0003 Significant 
TSH 10.4        0.64 9.62 1.44 3.56 1.45 2.68 0.98 0.0001 Significant 

DISCUSSION 
Many patients with chronic kidney disease have mild 
reduction in thyroid function or subclinical hypothyroidism – a 
condition that becomes more common as kidney function 
declines(CJASN).8
Prevalence of thyroid dysfunction in CRF      
According to the article published by the University of 
Southern California school of medicine, Los angels, USA, overall 
9.5% of patients with CKD had subclinical hypothyroidism. 7% of 
patients with mild CKD had low thyroid function, compared to 
18% of those with moderate CKD. After adjustment for other 
factors, patients with moderate CKD were 73% more likely to have 
abnormal thyroid function. 
Recently, Quion- verde et al have also reported higher 
prevalence of up to 5%  of frank hypothyroidism in patients with 
chronic renal failure,in comparison with hospitalised patients with 
normal renal function(0.6%).18
In an Indian study, conducted by Dept. of Nephrology, 
K.E.M Hospital, Mumbai, Maharastra, of 127 patients with CRF 
studied,93 patients (73%) showed significant [‘p’ value (<0.05)] 
reduction in their TT3,TT4,FT3 levels in serum.26
In our study, of the 40 patients studied, 3 pts (7.5%) had 
hypothyroidism, 6 patients (15%) had subclinical hypothyroidism 
and 17 patients (42.5%) had some thyroid hormone abnormalities 
in the form of reduction in TT3, TT4 and FT3 levels. So totally 65% 
of patients with CKD had thyroid hormone abnormalities. 
Prevalence of goitre in CKD  
Ramirez and associates, reported upto 58% prevalence of 
goitre in patients with CKD as compared to 8% in control areas 
from the same geographic area.16  
In a study conducted by Victoria sy lim and 
associates,reported 37% prevalence of goitre.27
In our study, of the 40 patients studied, 7 patients (17.5%) 
had goitre. 
Prevalence of symptomatic hypothyroidism in CKD  
Most of the CKD patients have low TT3, TT4, FT3 but 
normal FT4 and TSH levels in serum and they are clinically 
euthyroid. Some have overt hypothyroidism and even among them 
many patients are asymptomatic.4
In our study, 8 patients 20% were symptomatic and majority 
– 32 patients (80%) were asymptomatic. 
Relationship between CRF stage  and thyroid dysfunction: 
 Higher the stage of CKD, there is an increased prevalence of 
thyroid dysfunction in CRF patients.  
In our study, 13% of stage 5 CKD patients had 
hypothyroidism when compared to stage 3 (0%) and stage 4 (0%). 
21.7% of stage 5 patients had subclinical hypothyroidism when 
compared to stage 3 (0%) and stage 4(9.1%). Some hormone 
abnormalities according to stage 3,4&5 CKD were 16.7% 54.5% 
and 43.5% respectively. Overall the prevalence of thyroid hormone 
abnormalities in stage 3,4 and 5 CKD pts were 16.7%, 63.6% and 
78.2% respectively in our study. 
Despite the recent considerable improvements in renal 
replacement therapy, cardiovascular disease still remains the main 
cause of morbidity and mortality in CRF patients.22 It is evident 
from various studies conducted by Lindner, et al (1974)23, 
Stenvinkel, et al (1999)24, Cheung, et al(2000)25, and etc.,  
So many traditional and nontraditional risk factors are there 
for cardiovascular disease and its related morbidity and mortality. 
Apart  from them hypothyroidism and subclinical hypothyrodism 
are linked to an increased risk of cardiovascular disease and 
reduced cardiac function. 
Patients with CKD are at greatly increased risk of thyroid 
dysfunction. “Thyroid hormone abnormalities could represent a risk 
factor for cardiovascular disease and might also be implicated in 
kidney disease progression” – comments by authors Dr.Michel 
Chonchol of University of Colorado, Health Sciences Centre and 
Dr.Giovanni Targher of University of Verona, Italy.21 
 
 
 
 
 
 
 
 
 
 
 
  
CONCLUSION 
                                                                                                                     
 In our study, the overall prevalence of thyroid dysfunction is 
  65% in patients with chronic kidney disease. 
 7.5% of CKD patients had hypothyroidism. 
 15% had subclinical hypothyrodism. 
 42.5% had some thyroid hormone abnormalities. 
 17.5% of CKD patients had goiter. 
 There was a significant correlation between the prevalence of  
 thyroid dysfunction and the stage of chronic kidney disease. 
 Higher the degree of renal insufficiency, the higher was the 
 prevalence of thyroid hormone abnormalities. 
SUMMARY 
The patients with end stage renal disease have multiple 
alterations of thyroid hormone metabolism in the absence of 
concurrent thyroid disease. Higher the degree of renal 
insufficiency, there is an increased incidence of thyroid dysfunction 
in CRF patients. 
In the present study, a sample of 40 patients of CRF, admitted 
in medical and nephrology wards were assessed for the prevalence 
of thyroid dysfunction by estimating the thyroid hormones TT3, 
TT4, FT3, FT4 and TSH levels in serum. Patients belonged to the 
age group in the range of 23 to 75 years. 30 were males and 10 
were females. Among them 11 patients were diabetic and 29 were 
non diabetic.  
8 patients (20%) had symptoms suggestive of hypothyroidism 
and 7 patients (17.5%) had goitre on clinical examination.  
57.5% of patients belonged to stage 5 CKD. The overall 
prevalence of thyroid dysfunction was 65%. 
Data analysis was done by using the Epidemiological 
information package 2002.Among the variables studied, Blood urea 
(P= 0.0222), serum creatinine (p=0.0085). TT3 (p=0.0375), TT4 
(p=0.0254), FT3  (p=0.0043) and TSH (p=0.0031) were showed 
that there was a significant relationship between CRF stage and 
thyroid dysfunction. 
This study did not take into account the factor of dialysis. 
This study was designed to determine the prevalence of 
thyroid dysfunction in CRF patients in order to intervene at an early 
stage depending upon the hormone abnormalities and reduce both 
the risk of cardiovascular disease and progression of kidney 
dysfunction. 
TREATMENT OF THYROID DYSFUNCTION IN CRF: 
At present, there are no recommendations available regarding 
the treatment of thyroid hormone abnormalities in CRF patients. 
low thyroid state (low TT3, TT4, FT3) in uremia serves to defend 
against protein wasting and that misguided attempts to replete 
thyroid hormone stores may worsen protein malnutrition in CRF 
patients. 
But at the same time, subclinical and clinical hypothyroidism 
are associated with increased risk of cardiovascular disease and 
these conditions need treatment with thyroid hormone.  
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ABBREVIATIONS 
CKD  : Chronic Kidney Disease 
CRF  :  Chronic Renal Failure 
ESRD :  End Stage Renal Disease 
DM  : Diabetes Mellitus 
GFR  : Glomerular Filtration Rate 
Pcr  : Plasma Creatinine 
TT3  : Total Triiodothyronine 
TT4  : Total Thyroxine 
FT3   : Free Triiodothyronine 
FT4  :  Free Thyroxine 
TSH  : Thyroid Stimulating Hormone 
TRH  : Thyrotropine Releasing Hormone 
TBG  : Thyroid Binding Globulin 
EDV  : End Diastolic Volume 
SVR  : Systemic Vascular Resistance  
NO  : Nitric Oxide 
HT  : Hypertension 
LV  : Left Ventricle 
CRP  :  C  Reactive Protein  
LDL-c : Low Density Lipoprotein –cholesterol  
NKF  : National Kidney Foundation 
KDOQI : Kidney Dialysis Outcome Quality Initiative 
TPO  : Thyroid Peroxidase 
TBII  : TSH binding inhibiting immunoglobulin 
 
 MASTER CHART ABBREVIATIONS 
 
M  - MALE 
F  - FEMALE 
Y  - YES 
N  - NO 
 
NORMAL VALUES OF THYROID HORMONES 
TT3  - 60 – 200 ng/dl 
TT4  - 4.5 – 12 mcg / dl 
FT3  - 1.7 – 4.2 pg / ml 
FT4  - 0.7 – 1.8 ng/dl 
TSH  - 0.3 – 5.5 micro units / ml 
 
 
 
 
 
 
 
PROFORMA 
 
Name :  Age / Sex : Address : 
Admitted for :   Duration : 
Symptoms of Hypothyroidism:  Y / N  
 
Past H/o :  HT  Y/N DM    Y/N IHD Y/N 
  
 Hypothyroidism  Y/N  
 
Personal H/o:  Smoking  Y/N  Alcoholism  Y/N 
 
Family H/o :  Y/N 
 
General Examination :  Consciousness Normal / Abnormal  
   Anemia  + / -  
   Pedal edema + / -   
   Dry Skin + / -  
   Goitre + / -  
 
Vital Signs:  PR :   BP:  RR: T0 :
 U/O: 
Weight :   
 
Systemic Examination : CVS :  RS:  
 
   ABD :   CNS:  
 
Investigations:  
 
1. Bl.  Hb%   2. Urine :   alb  3. Bl : Sugar  
  TC     sug   Urea  
  DC     dep    Creatinine  
 
4. S.electrolytes :  Na+   5. ECG   
  K+ 
  Cl-
  HCo3-   6. Xray Chest  
7. Echo.:  
 
8. USG abdomen:  
 
  9. Thyroid profile: TT3: TT4: FT3: FT4: TSH: 
 
  Impression:  
 
Stage of CRF :  
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1 55 M Y N N 186 82 2.9 75 3.87 2.19 0.74 3.19 4 TT4 L
2 28 M N N N 84 65 2 100 4.99 1.6 0.77 2.8 3 FT3 L
3 54 M N N N 78 168 8.4 52 3.9 2.12 0.94 4.81 5 TT3, TT4 L
4 38 M Y Y Y 124 134 11.2 40 1.6 1.53 0.53 10.87 5 Hypothyroidism
5 37 F N N N 73 105 2.3 78 5 3.03 1.25 2.01 3 Normal
6 58 F Y Y Y 122 126 6.2 49 3.08 1.05 0.67 9.97 5 Hypothyroidism
7 35 M N N N 80 175 8.6 76 3.82 1.09 0.84 4.93 5 TT4, FT3 L
8 48 M N N N 84 72 2.4 108 6.47 2.28 0.93 1.46 3 Normal
9 55 F N N N 97 106 5.5 117 7.01 1.95 0.97 1.19 5 Normal
10 35 M N N N 68 134 4.9 100 5.7 1.93 0.8 8.58 5 Sub Clinical Hypothyroidism
11 70 M N Y N 75 148 9.6 40 1 1.1 0.45 >150 5 Hypothyroidism
12 38 M N N N 86 88 3.4 71 4.7 1.78 0.97 3.89 4 Normal
13 57 M N N N 100 68 2.1 105 6.8 2.41 1.19 1.78 3 Normal
14 55 M Y N N 160 93 3.6 69 4.38 1.72 0.88 0.77 4 TT4 L
15 50 M N N N 89 66 1.8 114 6.89 2.38 1.2 2.05 3 Normal
16 33 M N N N 78 198 12.3 45 3.3 1 0.92 1.17 5 TT3, TT4, FT3 L
17 50 M N N N 90 98 3.3 192 4.8 1.49 0.74 1.28 4 FT3 L
18 65 M Y N N 125 130 6.8 49 2.3 1.8 1.23 4.42 5 TT3, TT4 L
19 23 M N N N 85 120 3.8 160 6.8 3.12 1.39 3.96 4 Normal
20 47 M Y Y Y 96 183 10.8 88 5.3 2.12 0.94 12.34 5 Sub Clinical Hypothyroidism
21 53 M N N N 92 79 2.2 126 6.96 2.84 1.3 2.38 3 Normal
22 68 M N N N 89 98 5.2 80 4.96 2.2 1.19 3.06 5 Normal
23 59 M Y N N 118 110 5.9 127 6.88 1.95 0.97 1.89 5 Normal
24 75 M N N N 72 156 7.9 56 3.32 1.55 0.92 4.93 5 TT3, TT4, FT3 L
25 25 M N N N 71 92 3.3 102 5.96 2.88 0.93 4.16 4 Normal
26 55 M N N N 97 106 3.5 108 5.32 1.52 1.02 2.8 4 FT3 L
27 43 M N N N 85 97 3.7 72 3.8 2.28 1.14 2.35 4 TT4 L
28 46 M Y N N 134 120 9 58 4.16 1.48 0.94 3.96 5 TT3, TT4, FT3 L
29 58 M Y Y Y 98 144 7.8 82 5.02 3.16 0.89 9.68 5 Sub Clinical Hypothyroidism
30 27 F N N N 102 212 13.4 54 3.82 1.39 0.98 4.88 5 TT3, TT4 L
31 58 M N N N 80 117 6.2 98 6.8 2.62 1.2 2.96 5 Normal
32 48 F Y N N 140 78 3.3 120 6.82 1.8 1.32 3.24 4 Normal
33 54 F N Y Y 78 104 6.5 84 4.96 1.93 0.88 8.68 5 Sub Clinical Hypothyroidism
34 62 F N N N 96 98 5.9 102 5.38 1.89 1.08 3.42 5 Normal
35 31 F N Y Y 104 88 3.1 72 5.3 1.92 0.98 8.62 4 Sub Clinical Hypothyroidism
36 56 M N N N 86 170 9.2 56 3.9 1.88 0.9 4.84 5 TT3, TT4 L
37 45 M Y N N 136 117 8.1 80 4.1 1.09 0.93 4.46 5 TT4, FT3 L
38 44 F N Y Y 96 102 6.1 88 5.4 1.98 0.9 9.82 5 Sub Clinical Hypothyroidism
39 53 F N N N 88 110 6.8 90 3.62 1.12 0.97 4.55 5 TT4, FT3 L
40 47 M N N N 105 88 3.4 48 3.92 2.38 1.28 4.4 4 TT3, TT4 L
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